GI 4000

Drug Profile

GI 4000

Alternative Names: GI-4000

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlobeImmune
  • Developer GlobeImmune; NantCell
  • Class Cancer vaccines
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Suspended Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Nov 2017 NantKwest plans the phase I/II QUILT-3.060 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in November 2017 (NCT03329248)
  • 28 Aug 2017 GI 4000 licensed to NantCell worldwide
  • 01 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03136406)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top